We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Kronik hepatit b tedavisinde HBsAg ve M30 antijen titre takibinin klinik yararı.
- Authors
Ök, Zeynep Dündar; Çelik, Mustafa; Akbudak, İ̇smail Hakkı; Güleryüzlü, Yüksel; Yılmaz, Halil; Yılmaz, Mustafa
- Abstract
Purpose: Positive correlation has been detected between pretreatment and posttreatment serologic levels and amount of decrease of HbsAg and cccDNA. Serologic HbsAg level has also been correlated with cccDNA, and serologic HbsAg has been accepted to be a biomarker replacing cccDNA to diagnose infected cells. M30 antigen is used to detect CK 18 levels that are disintegrated by caspase proteins during apoptosis. As an indicator of apoptosis, M30 levels show liver injury in chronic Hepatitis B infection. In this study, we aimed to evaluate clinical efficacy of measurement of HbsAg and M30 titrated antigen levels for response to treatment of chronic Hepatitis B infection during follow-up. Materials and methods: Sixty patients receiving oral antiviral therapy for chronic Hepatitis B infection were included in the study. Correlation in between before treatment antigen levels of AST, ALT, HBVDNA, HAI, fibrosiswith HbsAg and M30 were evaluated in all patients. Before treatment and at sixth of month of treatment antigen level results of AST, ALT, HBVDNA, HbsAg and M30 were compared. Detected decrement levels following treatment were evaluated. In addition, patients were grouped in two according to medicine received by the patients as Lavumidin and Tenofovir. Two groups were compared concerning age, sex, pretreatment antigen levels of AST, ALT, HBVDNA, HAI, Fibrosis, HbsAg and M30. Two groups were also compared concerning posttreatment decrement ratio of antigen levels of HbsAg and M30. Results: Positive correlation was detected between levels of AST, ALT, HBVDNA and HbsAg and M30 antigens at pretreatment period measurements (p<0.001). While no significant correlation was detected between HAI, degree of Fibrosis and HbsAg (p>0.05), positive correlation was detected between HAI, degree of Fibrosis and m30 antigen levels (p<0.01). Statistically significant decrements of antigen levels of AST, ALT, HBVDNA, HbsAg and m30 were detected at posttreatment sixth month compared to pretreatment levels in all treated patients (p<0.001). There was no statistically significant difference between Lamivudin ve Tenofovir groups concerning decrement ratio of HBVDNA levels (p>0.05). However, the amount of decrease in antigen levels of HbsAg and m30 was statistically significantly more in Tenofovir group than Lamivudin group (p<0.001). Conclusion: Antigen level measurements of HbsAg and M30 can be used to detect severity of chronic hepatitis B infection and to evaluate effectiveness of the treatment. Significant decrease of HbsAg and M30 antigen levels in Tenofovir group in contrast to Lamivudin group showed us that treatment of chronic Hepatitis B infection with the most potent medicine can be effective to avoid cell death-apoptosis. For this reason, we propose that insisting on usage of oral antivirals with low resistance barrier just by observing ALT and HBVDNA results is inadvisable.
- Subjects
BIOMARKERS; APOPTOSIS; HEPATITIS B; ANTIVIRAL agents; CELL death
- Publication
Pamukkale Medical Journal, 2021, Vol 14, Issue 2, p380
- ISSN
1309-9833
- Publication type
Article
- DOI
10.31362/patd.826929